Active Ingredient History
Adderall and Mydayis are trade names for a combination drug called mixed amphetamine salts containing four salts of amphetamine. The mixture is composed of equal parts racemic amphetamine and dextroamphetamine, which produces a (3:1) ratio between dextroamphetamine and levoamphetamine, the two enantiomers of amphetamine. Both enantiomers are stimulants, but differ enough to give Adderall an effects profile distinct from those of racemic amphetamine or dextroamphetamine, which are marketed as Evekeo and Dexedrine/Zenzedi, respectively. Adderall is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used illicitly as an athletic performance enhancer, cognitive enhancer, appetite suppressant, and recreationally as a euphoriant. It is a central nervous system (CNS) stimulant of the phenethylamine class. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Affect (Phase 2)
Allergy and Immunology (Phase 1)
Alzheimer Disease (Phase 4)
Amphetamine-Related Disorders (Phase 2)
Anhedonia (Phase 1)
Autism Spectrum Disorder (Phase 2)
Bipolar Disorder (Phase 2)
Cannabis (Phase 2/Phase 3)
Central Nervous System Stimulants (Phase 2)
Cocaine-Related Disorders (Phase 2/Phase 3)
Cognitive Dysfunction (Phase 4)
Conduct Disorder (Phase 4)
COVID-19 (Phase 4)
Deficiency Diseases (Phase 4)
Dementia (Phase 4)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Drug Users (Phase 1)
Feeding and Eating Disorders (Phase 4)
Healthy Volunteers (Phase 4)
Idiopathic Hypersomnia (Phase 2)
Memory, Short-Term (Phase 2)
Methamphetamine (Phase 2)
Multiple Sclerosis (Phase 2/Phase 3)
Narcolepsy (Phase 2)
Neoplasms (Phase 2)
Opioid-Related Disorders (Phase 2)
Parenting (Phase 3)
Pharmacology (Phase 4)
Reading (Phase 4)
Schizophrenia (Phase 2)
Stress Disorders, Post-Traumatic (Phase 2)
Stroke (Phase 4)
Substance Abuse, Oral (Phase 1)
Substance-Related Disorders (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue